PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services.
PAION’s mission is to be a leading specialty pharmaceutical company in the fields of anesthesia and critical care by bringing novel products to market to benefit patients, doctors and other stakeholders in healthcare.
PAION's Strategy & Partnering
Teleconference & webcast
23. August 2021
PAION AG ANNOUNCES INITIATION OF PIVOTAL STUDY OF REMIMAZOLAM (BYFAVO(R)) IN...
DGAP-News: PAION AG / Key word(s): Study 16.09.2021 / 14:00 The...
PAION SIGNS EXCLUSIVE UK SUPPLY AND DISTRIBUTION AGREEMENT WITH CLINIGEN
DGAP-News: PAION AG / Key word(s): Miscellaneous 02.09.2021 /...
PAION LAUNCHES XERAVA(R) (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED...
DGAP-News: PAION AG / Key word(s): Market launch 01.09.2021 /...
I consent to the display of external content. This enables personal data to be transmitted to third-party platforms. Read more about our